EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN’S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL

Arthur Kaser  ¹     Bruce E. Sands  ²     Marijana Protic  ³     Laurent Peyrin-Biroulet  ⁴     Zhantao Lin     Rebecca Hozak     Vipul Jairath  ⁵     Hilde Carlier     Emily Hon     Monika Fischer  ^6    
1 University of Cambridge Gastroenterology and Hepatology, Cambridge, United Kingdom
² Icahn School of Medicine at Mount Sinai, New York, United States
³ Eli Lilly and Company, Indianapolis, United States
⁴ University Hospital of Nancy, University of Lorraine, Vandoeuvre-les-Nancy, France
⁵ Western University & London Health Sciences Centre, London, Canada
⁶ Indiana University, Indianapolis, United States

Topic
IBD

Session
IL-23: Many but different? (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)